AU2002343681B2 - Biocompatible polymer blends and uses thereof - Google Patents

Biocompatible polymer blends and uses thereof Download PDF

Info

Publication number
AU2002343681B2
AU2002343681B2 AU2002343681A AU2002343681A AU2002343681B2 AU 2002343681 B2 AU2002343681 B2 AU 2002343681B2 AU 2002343681 A AU2002343681 A AU 2002343681A AU 2002343681 A AU2002343681 A AU 2002343681A AU 2002343681 B2 AU2002343681 B2 AU 2002343681B2
Authority
AU
Australia
Prior art keywords
polymer
poly
biocompatible
composition
sustained release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002343681A
Other languages
English (en)
Other versions
AU2002343681A1 (en
Inventor
Henry R Costantino
Wendy W Nelson
Mark A Tracy
Kevin L Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Controlled Therapeutics Inc
Original Assignee
Alkermes Controlled Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Controlled Therapeutics Inc filed Critical Alkermes Controlled Therapeutics Inc
Publication of AU2002343681A1 publication Critical patent/AU2002343681A1/en
Application granted granted Critical
Publication of AU2002343681B2 publication Critical patent/AU2002343681B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002343681A 2001-11-12 2002-11-12 Biocompatible polymer blends and uses thereof Ceased AU2002343681B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33286801P 2001-11-12 2001-11-12
US60/332,868 2001-11-12
PCT/US2002/036365 WO2003041689A1 (en) 2001-11-12 2002-11-12 Biocompatible polymer blends and uses thereof

Publications (2)

Publication Number Publication Date
AU2002343681A1 AU2002343681A1 (en) 2003-07-24
AU2002343681B2 true AU2002343681B2 (en) 2006-07-06

Family

ID=23300202

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002343681A Ceased AU2002343681B2 (en) 2001-11-12 2002-11-12 Biocompatible polymer blends and uses thereof

Country Status (6)

Country Link
US (1) US7282216B2 (enExample)
EP (1) EP1443907A1 (enExample)
JP (1) JP2005510521A (enExample)
AU (1) AU2002343681B2 (enExample)
CA (1) CA2466998A1 (enExample)
WO (1) WO2003041689A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
DK1392254T3 (da) 2001-04-20 2007-07-02 Univ British Columbia Micelle-lægemiddelindgivelsessystem for hydrofobe lægemidler
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
FR2843117B1 (fr) * 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
FR2860516B1 (fr) * 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2862535B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interleukines et leurs applications therapeutiques
FR2862541B1 (fr) * 2003-11-21 2007-04-20 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
WO2005079856A1 (en) * 2004-02-23 2005-09-01 The University Of British Columbia Drug delivery compositions comprising hydrophobic polymers and amphipathic molecules
US8778014B1 (en) 2004-03-31 2014-07-15 Advanced Cardiovascular Systems, Inc. Coatings for preventing balloon damage to polymer coated stents
US20060198868A1 (en) * 2005-01-05 2006-09-07 Dewitt David M Biodegradable coating compositions comprising blends
US20060149363A1 (en) * 2005-01-06 2006-07-06 Scimed Life Systems, Inc. Optimally expanded, collagen sealed ePTFE graft with improved tissue ingrowth
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
US8192731B2 (en) * 2005-10-25 2012-06-05 Loctite (R&D) Limited Thickened cyanoacrylate compositions
WO2008157540A1 (en) * 2007-06-20 2008-12-24 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
KR20100056479A (ko) 2007-07-25 2010-05-27 바이오렉스 쎄라퓨틱스, 인코포레이티드 제어 방출 인터페론 약물 제품 및 이를 사용한 ｈｃｖ 감염의 치료
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
AU2010234916A1 (en) * 2009-03-30 2011-10-13 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
US8883208B2 (en) * 2009-04-08 2014-11-11 Surmodics, Inc. Particles for delivery of nucleic acids and related devices and methods
EP2416762A2 (en) * 2009-04-08 2012-02-15 SurModics, Inc. Controlled release devices and methods for delivery of nucleic acids
MX2012012001A (es) 2010-04-16 2013-05-01 Apatech Ltd Biomaterial.
US9173978B2 (en) 2010-09-22 2015-11-03 Ethicon, Inc. Bioabsorbable polymeric compositions, processing methods, and medical devices therefrom
WO2013082503A1 (en) * 2011-12-01 2013-06-06 Flow Pharma, Inc. Peptide particle formulation
WO2013086419A1 (en) * 2011-12-09 2013-06-13 California Institute Of Technology Polymer scaffolds and their use in the treatment of vision loss
ES2612530T3 (es) * 2012-03-30 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Composición de microesferas, método de preparación y aplicaciones de la misma
US20150044147A1 (en) * 2013-02-18 2015-02-12 King Abdullah International Medical Research Center Composition for management of periodontal disease
EP2986323A4 (en) * 2013-04-16 2016-10-19 Univ Case Western Reserve NEUTRALLY LOADED SYNTHETIC BLOOD PLATES TO REDUCE A COMPLEMENT REACTION
US9775929B2 (en) * 2014-04-14 2017-10-03 University Of Maryland College Park Solution blow spun polymer fibers, polymer blends therefor and methods and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3378250D1 (en) * 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
JP4979843B2 (ja) 1995-03-10 2012-07-18 ロッシュ ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 微粒子の形のポリペプチド含有投薬形
US5709852A (en) * 1995-12-05 1998-01-20 Basf Corporation Ethylene oxide/propylene oxide/ethylene oxide (EO/PO/EO) triblock copolymer carrier blends
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
WO2001041735A2 (en) 1999-12-07 2001-06-14 Amgen Inc. Thermosensitive biodegradable hydrogels based on low molecular weight pluronics
US6296842B1 (en) * 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties

Also Published As

Publication number Publication date
JP2005510521A (ja) 2005-04-21
WO2003041689A1 (en) 2003-05-22
EP1443907A1 (en) 2004-08-11
CA2466998A1 (en) 2003-05-22
US7282216B2 (en) 2007-10-16
US20030133980A1 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
AU2002343681B2 (en) Biocompatible polymer blends and uses thereof
AU2002343681A1 (en) Biocompatible polymer blends and uses thereof
US6455074B1 (en) Methods for fabricating polymer-based controlled release devices
US6479065B2 (en) Process for the preparation of polymer-based sustained release compositions
US6296842B1 (en) Process for the preparation of polymer-based sustained release compositions
AU2002244314B2 (en) Modification of the sustained release profile
EP0644771B2 (en) Erythropoietin drug delivery system
AU772910B2 (en) Method of producing submicron particles of a labile agent
AU761472B2 (en) Method of producing sub-micron particles of biologically active agents
AU2002244314A1 (en) Modification of the sustained release profile
HU221602B (hu) Fémkationnal komplexet képező, interferont tartalmazó, szabályozott hatóanyag-leadású gyógyszerkészítmény
WO1998007412A1 (en) Controlled release microparticles with a hydrophobic material
US20060269602A1 (en) Method of modifying the release profile of sustained release compositions
AU2005238511A1 (en) Low molecular weight polylactic acid polymers
WO2001058428A1 (en) Method of preparing a sustained release composition

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired